Get the Stockscreener App
36.48
0.73%
-0.27
After Hours:
36.36
-0.12
-0.33%
Overview
News
Price History
Option Chain
Why NVO Down?
Discussions
Forecast
Stock Split
Dividend History
Novo Nordisk Adr stock is traded at $36.48, with a volume of 23.99M.
It is down -0.73% in the last 24 hours and down -2.59% over the past month.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
See More
Previous Close:
$36.75
Open:
$36.77
24h Volume:
23.99M
Relative Volume:
1.03
Market Cap:
$161.96B
Revenue:
$46.77B
Net Income/Loss:
$15.45B
P/E Ratio:
10.52
EPS:
3.468
Net Cash Flow:
$4.40B
1W Performance:
+0.41%
1M Performance:
-2.59%
6M Performance:
-38.35%
1Y Performance:
-46.38%
1-Day Range:
$35.78
$37.09
1-Week Range:
$35.12
$37.44
52-Week Range:
$35.12
$81.44
Novo Nordisk Adr Stock (NVO) Company Profile
Name
Novo Nordisk Adr
Sector
Industry
Phone
-
Address
-
Compare NVO vs LLY, JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
36.48 | 163.16B | 46.77B | 15.45B | 4.40B | 3.468 |
LLY
Lilly Eli Co
|
954.52 | 821.68B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
244.12 | 588.76B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
214.98 | 384.69B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
200.73 | 305.86B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.84 | 297.40B | 64.93B | 18.26B | 12.36B | 7.2751 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-26 | Initiated | Wolfe Research | Peer Perform |
| Mar-18-26 | Initiated | Bernstein | Outperform |
| Mar-10-26 | Downgrade | TD Cowen | Buy → Hold |
| Mar-03-26 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-02-26 | Downgrade | Goldman | Buy → Neutral |
| Feb-24-26 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-24-26 | Downgrade | Kepler | Buy → Hold |
| Feb-23-26 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-12-26 | Upgrade | Jefferies | Underperform → Hold |
| Jan-27-26 | Initiated | Citigroup | Neutral |
| Dec-08-25 | Downgrade | Argus | Buy → Hold |
| Oct-27-25 | Resumed | Jefferies | Underperform |
| Oct-01-25 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-29-25 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Sep-16-25 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Sep-09-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-13-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Aug-05-25 | Downgrade | UBS | Buy → Neutral |
| Jul-31-25 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-30-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-17-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Mar-13-25 | Upgrade | Kepler | Hold → Buy |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-12-25 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-06-25 | Upgrade | Bernstein | Underperform → Mkt Perform |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-12-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Neutral |
| Dec-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-02-23 | Initiated | Argus | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-15-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-28-22 | Downgrade | UBS | Neutral → Sell |
| Jun-27-22 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
| Jun-07-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-31-22 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-22 | Upgrade | Cowen | Market Perform → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-16-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-25-22 | Downgrade | Liberum | Hold → Sell |
| Dec-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-17-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-20-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jul-06-20 | Downgrade | BofA Securities | Buy → Neutral |
| May-11-20 | Downgrade | UBS | Buy → Neutral |
| May-04-20 | Initiated | Cowen | Market Perform |
| Mar-16-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-20 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-18-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-17-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-30-19 | Downgrade | Jefferies | Hold → Underperform |
| Jun-20-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-11-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Apr-29-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-29-19 | Initiated | Exane BNP Paribas | Outperform |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Dec-29-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-06-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-01-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-25-17 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Sep-06-17 | Upgrade | BofA/Merrill | Underperform → Neutral |
View All
Novo Nordisk Adr Stock (NVO) Latest News
Why Eli Lilly Stock Trounced the Market Today - The Motley Fool
Novo Nordisk (NYSE: NVO) details progress on DKK 15bn share repurchase - Stock Titan
NVO Stock Price, Quote & Chart | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - chartmill.com
Novo Nordisk A/S Stock: Pipeline Innovations Amid Share Price Pressures and Market Challenges - ad-hoc-news.de
Novo Nordisk Voucher Win Meets Rising Scrutiny Of FDA Review Program - Sahm
Novo Nordisk A/S Stock: FDA Approval for Awiqli Bolsters Diabetes Portfolio Amid 2026 Market Recover - ad-hoc-news.de
Novo Nordisk A/S Stock: Recent AGM Resolutions Reinforce Dual-Class Structure and Dividend Strength - ad-hoc-news.de
NVO Stock Chart | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - chartmill.com
NVO Stock Quote Price and Forecast - CNN
NVO Technical Analysis | Trend, Signals & Chart Patterns | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - ChartMill
Novo Nordisk A/S stock faces pressure amid shifting obesity drug landscape and analyst hold rating - ad-hoc-news.de
Novo Nordisk A/S stock faces analyst scrutiny amid Wegovy demand questions and Equal Weight rating h - ad-hoc-news.de
Novo Nordisk A/S stock faces FDA warnings on GLP-1 drugs amid rising competition pressures - ad-hoc-news.de
NVO Price History for Novo Nordisk A/S ADR Stock - Barchart.com
Novo Nordisk Secures FDA Approval For Higher-Dose Wegovy - Sahm
Novo Nordisk A/S stock faces pressure from FDA warning on semaglutide reporting and Bernstein Underp - AD HOC NEWS
Novo Nordisk A/S stock faces headwinds from CagriSema trial setback amid buyback progress and compet - AD HOC NEWS
Novo Nordisk A/S stock rebounds on UBT251 trial data amid CEO turmoil and buyback momentum - AD HOC NEWS
Novo Nordisk A/S - GlobeNewswire Inc.
Novo Nordisk A/S Stock (ISIN: DK0062498333) Faces Headwinds from FDA Warning Amid GLP-1 Demand - ad-hoc-news.de
Novo Nordisk A/S Stock Faces Brutal Choice: Can Oral Wegovy Rescue the Semaglutide Empire? - AD HOC NEWS
FDA Warning Tests Novo Nordisk Compliance And Reshapes NYSE NVO Risk Profile - Sahm
Novo Nordisk Telehealth Deal Weighs On Weak Share Price And Valuation - sahmcapital.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/SNVO - Finansavisen
Novo Nordisk A/S (NVO) Expands Manufacturing to Support Rising Global Demand for GLP-1 Drugs - Finviz
Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal - Finviz
Novo Nordisk 2026 Dividend Guide for UAE Investors - Bitget
Morgan Stanley Upgrades Novo Nordisk A/S (NVO) to Equal Weight From UnderweightHere's Why - Finviz
Novo Nordisk Faces Securities Probe And GLP-1 Compounding Crackdown - sahmcapital.com
Novo Nordisk (NVO) Reports 10% Sales Growth as Obesity Care Hits DKK 82B - Finviz
Novo Nordisk Adr Stock (NVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):